The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Quinaprilat     (3S)-2-[(2S)-2-[[(1S)-1- carboxy-3-phenyl...

Synonyms: CHEMBL1733, SureCN113237, CI-928, KST-1A8900, NSC-759825, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of CI 928


High impact information on CI 928


Chemical compound and disease context of CI 928


Biological context of CI 928


Anatomical context of CI 928


Associations of CI 928 with other chemical compounds


Gene context of CI 928


Analytical, diagnostic and therapeutic context of CI 928


  1. Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure. Mitrovic, V., Mudra, H., Bonzel, T., Schmidt, W., Strand, J.C., Bakovic-Alt, R., Posvar, E.L. Clin. Pharmacol. Ther. (1996) [Pubmed]
  2. Assessing the clinical need for short-term conversion from oral to parenteral angiotensin converting enzyme inhibitor therapy in hypertensive patients. A quinapril to quinaprilat placebo-controlled model. Whelton, A., McCormick, L., Wombolt, D., Goldstein, R., Canter, D. Eur. Heart J. (1997) [Pubmed]
  3. Quinaprilat during cardioplegic arrest in the rabbit to prevent ischemia-reperfusion injury. Korn, P., Kröner, A., Schirnhofer, J., Hallström, S., Bernecker, O., Mallinger, R., Franz, M., Gasser, H., Wolner, E., Podesser, B.K. J. Thorac. Cardiovasc. Surg. (2002) [Pubmed]
  4. Effect of intraoperative angiotensin-converting enzyme inhibition by quinaprilat on hypertension after coronary artery surgery. Müller, M., Schindler, E., Kwapisz, M., Klemm, S., Akintürk, H., Heidt, M., Hempelmann, G. British journal of anaesthesia. (2000) [Pubmed]
  5. Pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients on chronic hemodialysis. Blum, R.A., Olson, S.C., Kohli, R.K., Horvath, A.M., Sedman, A.J., Posvar, E.L. Journal of clinical pharmacology. (1990) [Pubmed]
  6. Quinaprilat induces arterial vasodilation mediated by nitric oxide in humans. Haefeli, W.E., Linder, L., Lüscher, T.F. Hypertension (1997) [Pubmed]
  7. ACE inhibitors in the treatment of hypertension in the older patient. Canter, D., Frank, G. Eur. Heart J. (1990) [Pubmed]
  8. Beneficial effects of quinaprilat on coronary vasomotor function, endothelial oxidative stress, and endothelin activation after human heart transplantation. Steinhauff, S., Pehlivanli, S., Bakovic-Alt, R., Meiser, B.M., Becker, B.F., von Scheidt, W., Weis, M. Transplantation (2004) [Pubmed]
  9. The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure. Begg, E.J., Robson, R.A., Ikram, H., Richards, A.M., Bammert-Adams, J.A., Olson, S.C., Posvar, E.L., Reece, P.A., Sedman, A.J. British journal of clinical pharmacology. (1994) [Pubmed]
  10. Improvement of bradykinin endothelium-mediated vasodilation of forearm resistance circulation by quinaprilat in patients with coronary artery disease with or without left ventricular dysfunction. Benacerraf, S., Carville, C., Adnot, S., Montagne, O., Sediame, S., Belhassen, L., Dubois-Randé, J.L. J. Cardiovasc. Pharmacol. (1999) [Pubmed]
  11. Quinaprilat increases total body vascular compliance in rats with myocardial infarction. Chien, Y., Frohlich, E.D., MacPhee, A.A., Pegram, B.L. Chin. Med. J. (1992) [Pubmed]
  12. Antihypertensive effects and arterial haemodynamic alterations during angiotensin converting enzyme inhibition. London, G.M., Pannier, B., Vicaut, E., Guérin, A.P., Marchais, S.J., Safar, M.E., Cuche, J.L. J. Hypertens. (1996) [Pubmed]
  13. Single-domain angiotensin I converting enzyme (kininase II): characterization and properties. Deddish, P.A., Wang, L.X., Jackman, H.L., Michel, B., Wang, J., Skidgel, R.A., Erdös, E.G. J. Pharmacol. Exp. Ther. (1996) [Pubmed]
  14. Pharmacokinetics of quinapril in children: assessment during substitution for chronic angiotensin-converting enzyme inhibitor treatment. Blumer, J.L., Daniels, S.R., Dreyer, W.J., Batisky, D., Walson, P.D., Roman, D., Ouellet, D. Journal of clinical pharmacology. (2003) [Pubmed]
  15. Pharmacokinetics of quinapril and its active metabolite quinaprilat during continuous ambulatory peritoneal dialysis. Swartz, R.D., Starmann, B., Horvath, A.M., Olson, S.C., Posvar, E.L. Journal of clinical pharmacology. (1990) [Pubmed]
  16. Angiotensin I-converting enzyme inhibitors block protein kinase C epsilon by activating bradykinin B1 receptors in human endothelial cells. Stanisavljevic, S., Ignjatovic, T., Deddish, P.A., Brovkovych, V., Zhang, K., Erdös, E.G., Skidgel, R.A. J. Pharmacol. Exp. Ther. (2006) [Pubmed]
  17. Quinapril and its metabolite quinaprilat in human milk. Begg, E.J., Robson, R.A., Gardiner, S.J., Hudson, L.J., Reece, P.A., Olson, S.C., Posvar, E.L., Sedman, A.J. British journal of clinical pharmacology. (2001) [Pubmed]
  18. Regulation of pressure-activated channel in intact vascular endothelium of stroke-prone spontaneously hypertensive rats. Köhler, R., Grundig, A., Brakemeier, S., Rothermund, L., Distler, A., Kreutz, R., Hoyer, J. Am. J. Hypertens. (2001) [Pubmed]
  19. Captopril and quinapril reduce reactive oxygen species. van der Giet, M., Erinola, M., Zidek, W., Tepel, M. Eur. J. Clin. Invest. (2002) [Pubmed]
  20. Quinaprilat increases total body vascular compliance in rats with myocardial infarction. Chien, Y., Frohlich, E.D., MacPhee, A.A., Pegram, B.L. J. Cardiovasc. Pharmacol. (1992) [Pubmed]
  21. L-NAME-resistant bradykinin-induced relaxation in porcine coronary arteries is NO-dependent: effect of ACE inhibition. Danser, A.H., Tom, B., de Vries, R., Saxena, P.R. Br. J. Pharmacol. (2000) [Pubmed]
  22. The effect of proteinase inhibitors on glomerular albumin permeability induced in vitro by serum from patients with idiopathic focal segmental glomerulosclerosis. Carraro, M., Zennaro, C., Artero, M., Candiano, G., Ghiggeri, G.M., Musante, L., Sirch, C., Bruschi, M., Faccini, L. Nephrol. Dial. Transplant. (2004) [Pubmed]
  23. Multiple-dose cimetidine administration does not influence the single-dose pharmacokinetics of quinapril and its active metabolite (CI-928). Ferry, J.J., Cetnarowski, A.B., Sedman, A.J., Thomas, R.W., Horvath, A.M. Journal of clinical pharmacology. (1988) [Pubmed]
  24. Effects of renin-angiotensin system in mediating endothelin-induced renal vasoconstriction: therapeutic implications. Chan, D.P., Clavell, A., Keiser, J., Burnett, J.C. Journal of hypertension. Supplement : official journal of the International Society of Hypertension. (1994) [Pubmed]
  25. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Pörsti, I., Bara, A.T., Busse, R., Hecker, M. Br. J. Pharmacol. (1994) [Pubmed]
  26. Trace analysis of quinapril and its active metabolite, quinaprilat, in human plasma and urine by gas chromatography-negative-ion chemical ionization mass spectrometry. Goto, N., Kamata, T., Ikegami, K. J. Chromatogr. (1992) [Pubmed]
  27. Localization of carboxypeptidase A-like enzyme in rat kidney. Igić, R., Garber, S., Sekosan, M., Urbanska, R.A., Behnia, R. Peptides (2003) [Pubmed]
  28. A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril. Breslin, E., Posvar, E., Neub, M., Trenk, D., Jahnchen, E. Journal of clinical pharmacology. (1996) [Pubmed]
WikiGenes - Universities